A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
Clinical trial NCT04718844 · COMPLETED
Trial details
- NCT number
- NCT04718844
- Sponsor
- Silence Therapeutics plc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-14
- Primary completion
- 2023-05-23
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.